

Supplemental material is neither peer-reviewed nor thoroughly edited by CJASN. The authors alone are responsible for the accuracy and presentation of the material.

SUPPLEMENTAL MATERIAL TABLE OF CONTENTS

Supplemental Table 1. Multivariable-adjusted cross-sectional associations of baseline characteristics with T₅₀

Supplemental Table 2. Associations of T₅₀ with atherosclerotic cardiovascular disease and heart failure events in CRIC Study participants without self-reported history of cardiovascular disease

Supplemental Table 3. Impact of adjustment for additional variables on associations of T₅₀ with clinical events

Supplemental Figure 1. Scatterplot and correlation coefficient of estimated glomerular filtration rate and T₅₀

Supplemental Table 1. Multivariable-adjusted cross-sectional associations of baseline characteristics with T₅₀

Variables ^a	β (95% CI)	Standardized β (95% CI) ^b	Wald X ²	P Value
Age, years	0.14 (-0.12, 0.40)	1.50 (-1.31, 4.32)	1.10	0.30
Female sex	-6.02 (-11.57, -0.48)	-3.00 (-5.76, -0.24)	4.53	0.03
Race/ethnicity (reference = non-Hispanic white)				
Non-Hispanic black	-23.63 (-32.46, -14.80)	-10.17 (-13.04, -7.30)	48.32	<0.001
Hispanic	-20.65 (-26.47, -14.83)	-7.58 (-10.41, -4.75)	27.51	<0.001
Other	8.52 (-4.70, 21.74)	1.68 (-0.92, 4.27)	1.60	0.21
Current cigarette smoking	-4.17 (-12.13, 3.80)	-1.36 (-3.95, 1.24)	1.05	0.31
History of cardiovascular disease	-2.19 (-7.89, 3.51)	-1.05 (-3.78, 1.68)	0.57	0.45
Diabetes mellitus	-9.62 (-15.21, -4.04)	-4.81 (-7.61, -2.02)	11.40	<0.001
Systolic blood pressure, mmHg	0.00 (-0.14, 0.13)	-0.11 (-2.94, 2.73)	0.01	0.94
Antihypertensive medication use	8.12 (-1.98, 18.22)	2.19 (-0.54, 4.92)	2.48	0.12
Total cholesterol, mg/dL	0.08 (0.02, 0.14)	3.54 (0.77, 6.31)	6.29	0.01
High-density lipoprotein cholesterol, mg/dL	0.01 (-0.18, 0.19)	0.10 (-2.75, 2.95)	0.00	0.95
Estimated glomerular filtration rate, ml/min/1.73 m ²	0.93 (0.76, 1.11)	15.85 (12.91, 18.78)	112.14	<0.001
Urinary protein, g/24h	-1.81 (-3.12, -0.50)	-4.10 (-7.07, -1.12)	7.29	0.007

^a Adjusted for all other variables in the model

^b Standardization of the regression coefficients models all variables on the same scale (mean, 0; standard deviation, 1) which allows coefficient-to-coefficient comparisons. Higher magnitudes of the standardized β suggest a stronger relative association with baseline T₅₀.

BP, blood pressure; CI, confidence interval; CVD, cardiovascular disease; eGFR, estimated glomerular filtration rate; HDL, high-density lipoprotein

Supplemental material is neither peer-reviewed nor thoroughly edited by CJASN. The authors alone are responsible for the accuracy and presentation of the material.

Supplemental Table 2. Associations of T₅₀ with atherosclerotic cardiovascular disease and heart failure events in CRIC Study participants without self-reported history of cardiovascular disease

	Quartiles of T ₅₀ , min				Per 1-SD Lower T ₅₀ (79 min)	P Value
	Quartile 4 (≥364 min)	Quartile 3 (318-363 min)	Quartile 2 (264-317 min)	Q1 Quartile 1 (≤263 min)		
Atherosclerotic Cardiovascular Disease (n=2180)						
Events / Total Number	47 / 582	55 / 543	58 / 563	64 / 492		
Hazard ratio (95% CI)						
Unadjusted	Reference	1.25 (0.85-1.85)	1.36 (0.93-2.00)	1.83 (1.26-2.67)	1.22 (1.07-1.40)	0.003
Model 1 ^a	Reference	1.16 (0.78-1.72)	1.29 (0.87-1.90)	1.73 (1.17-2.55)	1.22 (1.06-1.40)	0.007
Model 2 ^b	Reference	1.16 (0.79-1.73)	1.20 (0.81-1.78)	1.51 (1.02-2.23)	1.15 (1.00-1.33)	0.06
Model 3 ^c	Reference	1.02 (0.69-1.52)	1.02 (0.68-1.52)	1.15 (0.76-1.73)	1.04 (0.89-1.20)	0.64
Congestive Heart Failure (n=2180)						
Events / Total Number	49 / 582	57 / 543	66 / 563	67 / 492		
Hazard ratio (95% CI)						
Unadjusted	Reference	1.24 (0.85-1.82)	1.47 (1.01-2.13)	1.83 (1.27-2.65)	1.21 (1.07-1.38)	0.003
Model 1 ^a	Reference	1.08 (0.73-1.58)	1.24 (0.85-1.81)	1.47 (1.00-2.15)	1.13 (0.98-1.29)	0.09
Model 2 ^b	Reference	1.07 (0.73-1.57)	1.14 (0.78-1.67)	1.22 (0.83-1.80)	1.05 (0.92-1.21)	0.45
Model 3 ^c	Reference	0.92 (0.62-1.37)	0.95 (0.64-1.40)	0.85 (0.57-1.28)	0.92 (0.80-1.06)	0.26

^a Model 1: adjusted for age, sex, race/ethnicity

^b Model 2: adjusted for variables in model 1 + history of CVD, history of diabetes, systolic BP, use of antihypertensive medications, total cholesterol, HDL cholesterol, and current smoking

^c Model 3: adjusted for variables in model 2 + eGFR and 24-hour urinary protein

BP, blood pressure; CI, confidence interval; CVD, cardiovascular disease; eGFR, estimated glomerular filtration rate; HDL, high-density lipoprotein

Supplemental Table 3. Impact of adjustment for additional variables on associations of T₅₀ with clinical events

	Quartiles of T ₅₀ , min				Per 1-SD Lower T ₅₀ (79 min)	P Value
	Quartile 4 (≥364 min)	Quartile 3 (318-363 min)	Quartile 2 (264-317 min)	Q1 Quartile 1 (≤263 min)		
Atherosclerotic Cardiovascular Disease, Hazard ratio (95% CI)						
Model 3 ^a	Reference	1.22 (0.94-1.57)	1.30 (1.01-1.68)	1.14 (0.88-1.48)	1.07 (0.98-1.17)	0.14
Model 4 ^b	Reference	1.19 (0.91-1.56)	1.28 (0.98-1.69)	1.13 (0.84-1.50)	1.08 (0.97-1.19)	0.15
Model 5 ^c	Reference	1.19 (0.92-1.54)	1.25 (0.97-1.62)	1.11 (0.86-1.44)	1.06 (0.97-1.16)	0.20
Congestive Heart Failure, Hazard ratio (95% CI)						
Model 3 ^a	Reference	0.83 (0.65-1.06)	0.95 (0.75-1.20)	0.85 (0.67-1.07)	0.95 (0.88-1.03)	0.25
Model 4 ^b	Reference	0.79 (0.61-1.01)	0.91 (0.70-1.18)	0.76 (0.59-1.00)	0.91 (0.83-1.00)	0.05
Model 5 ^c	Reference	0.80 (0.63-1.02)	0.93 (0.73-1.18)	0.82 (0.65-1.05)	0.95 (0.87-1.03)	0.20
All-cause Mortality, Hazard Ratio (95% CI)						
Model 3 ^a	Reference	0.96 (0.79-1.18)	1.13 (0.93-1.37)	1.09 (0.89-1.32)	1.05 (0.98-1.12)	0.17
Model 4 ^b	Reference	0.89 (0.72-1.10)	1.05 (0.85-1.30)	0.90 (0.72-1.12)	0.97 (0.90-1.05)	0.42
Model 5 ^c	Reference	0.94 (0.77-1.15)	1.10 (0.90-1.35)	1.05 (0.86-1.29)	1.04 (0.97-1.11)	0.31
Cardiovascular Mortality, Hazard Ratio (95% CI)						
Model 3 ^a	Reference	0.85 (0.61-1.18)	1.22 (0.89-1.67)	0.99 (0.72-1.36)	1.01 (0.91-1.13)	0.81
Model 4 ^b	Reference	0.85 (0.60-1.20)	1.22 (0.87-1.71)	0.94 (0.66-1.34)	0.98 (0.87-1.11)	0.77
Model 5 ^c	Reference	0.84 (0.60-1.17)	1.19 (0.87-1.64)	0.98 (0.71-1.35)	1.01 (0.90-1.12)	0.92
Non-cardiovascular Mortality, Hazard Ratio (95% CI)						
Model 3 ^a	Reference	1.04 (0.77-1.41)	1.09 (0.81-1.47)	1.30 (0.97-1.74)	1.12 (1.01-1.24)	0.03
Model 4 ^b	Reference	0.92 (0.67-1.27)	0.96 (0.70-1.33)	0.98 (0.71-1.36)	1.01 (0.90-1.13)	0.90
Model 5 ^c	Reference	1.01 (0.74-1.36)	1.05 (0.78-1.42)	1.23 (0.92-1.64)	1.10 (0.99-1.22)	0.07
End-stage Renal Disease, Hazard Ratio (95% CI)						
<i>Years 0 to <3</i>						
Model 3 ^a	Reference	1.08 (0.74-1.58)	0.90 (0.62-1.31)	1.12 (0.78-1.60)	1.05 (0.94-1.17)	0.43
Model 4 ^b	Reference	1.03 (0.70-1.52)	0.91 (0.62-1.33)	1.02 (0.70-1.48)	0.98 (0.87-1.10)	0.76
Model 5 ^c	Reference	1.09 (0.74-1.60)	0.92 (0.63-1.35)	1.14 (0.80-1.62)	1.05 (0.94-1.17)	0.41
<i>Years 3 to 12</i>						
Model 3 ^a	Reference	0.88 (0.67-1.14)	0.79 (0.60-1.02)	0.78 (0.60-1.03)	0.93 (0.85-1.03)	0.17
Model 4 ^b	Reference	0.84 (0.64-1.10)	0.77 (0.58-1.02)	0.76 (0.57-1.02)	0.92 (0.83-1.03)	0.15
Model 5 ^c	Reference	0.86 (0.66-1.12)	0.77 (0.59-1.01)	0.79 (0.60-1.04)	0.94 (0.85-1.04)	0.21

^a Model 3: adjusted for age, sex, race/ethnicity, history of CVD, history of diabetes, systolic BP, use of antihypertensive medications, total cholesterol, HDL cholesterol, current smoking, eGFR and 24-hour urinary protein

^b Model 4: adjusted for variables in model 3 + calcium, phosphate, bicarbonate, magnesium, serum albumin, fetuin-A, fibroblast growth factor-23, parathyroid hormone, use of warfarin medication, and use of active vitamin D, phosphate binder, or calciferol medications

^c Model 5: adjusted for variables in model 3 + high-sensitivity C-reactive protein and interleukin-6

Supplemental material is neither peer-reviewed nor thoroughly edited by CJASN. The authors alone are responsible for the accuracy and presentation of the material.

BP, blood pressure; CI, confidence interval; CVD, cardiovascular disease; eGFR, estimated glomerular filtration rate; HDL, high-density lipoprotein

Supplemental material is neither peer-reviewed nor thoroughly edited by CJASN. The authors alone are responsible for the accuracy and presentation of the material.

Supplemental Figure 1. Scatterplot and correlation coefficient of estimated glomerular filtration rate and T₅₀

